Treatment of focal degenerative cartilage defects with polymer-based autologous chondrocyte grafts: four-year clinical results

Kreuz, P C; Müller, S; Ossendorf, C; Kaps, C; Erggelet, C
Treatment of focal degenerative cartilage defects with polymer-based autologous chondrocyte grafts: four-year clinical results

Abstract

INTRODUCTION: Second-generation autologous chondrocyte implantation with scaffolds stabilizing the grafts is a clinically effective procedure for cartilage repair. In this ongoing prospective observational case report study, we evaluated the effectiveness of BioSeed-C, a cell-based cartilage graft based on autologous chondrocytes embedded in fibrin and a stable resorbable polymer scaffold, for the treatment of clinical symptomatic focal degenerative defects of the knee. METHODS: Clinical outcome after 4-year clinical follow-up was assessed in 19 patients with preoperatively radiologically confirmed osteoarthritis and a Kellgren-Lawrence score of 2 or more. Clinical scoring was performed before implantation of the graft and 6, 12, and 48 months after implantation using the Lysholm score, the Knee injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee (IKDC) score, and the International Cartilage Repair Society (ICRS) score. Cartilage regeneration and articular resurfacing were assessed by magnetic resonance imaging (MRI) 4 years after implantation of the autologous cartilage graft. RESULTS: Significant improvement (P < 0.05) of the Lysholm and ICRS scores was observed as early as 6 months after implantation of BioSeed-C and remained stable during follow-up. The IKDC score showed significant improvement compared with the preoperative situation at 12 and 48 months (P < 0.05). The KOOS showed significant improvement in the subclasses pain, activities of daily living, and knee-related quality of life 6 months as well as 1 and 4 years after implantation of BioSeed-C in osteoarthritic defects (P < 0.05). MRI analysis showed moderate to complete defect filling with a normal to incidentally hyperintense signal in 16 out of 19 patients treated with BioSeed-C. Two patients without improvement in the clinical and MRI scores received a total knee endoprosthesis after 4 years. CONCLUSIONS: The results show that the good clinical outcome achieved 1 year after implantation of BioSeed-C remains stable over the course of a period of 4 years and suggest that implanting BioSeed-C is a promising treatment option for the repair of focal degenerative defects of the knee.
Research article

Treatment of focal degenerative cartilage defects with polymer-based autologous chondrocyte grafts: four-year clinical results

Peter C Kreuz1, Sebastian Müller2, Christian Ossendorf2, Christian Kaps3 and Christoph Erggelet2

1Department of Orthopaedic and Trauma Surgery, University Medical Center Rechts der Isar of the Technical University Munich, Ismaninger Str. 22, 81675 Munich, Germany
2Department of Orthopaedic and Trauma Surgery, University Medical Center Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany
3Department of Rheumatology, Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

Corresponding author: Christian Kaps, christian.kaps@charite.de

Received: 18 Sep 2008 Revisions requested: 28 Oct 2008 Revisions received: 4 Feb 2009 Accepted: 5 Mar 2009 Published: 5 Mar 2009

Arthritis Research & Therapy 2009, 11:R33 (doi:10.1186/ar2638)
This article is online at: http://arthritis-research.com/content/11/2/R33
© 2009 Kreuz et al.; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction Second-generation autologous chondrocyte implantation with scaffolds stabilizing the grafts is a clinically effective procedure for cartilage repair. In this ongoing prospective observational case report study, we evaluated the effectiveness of BioSeed®-C, a cell-based cartilage graft based on autologous chondrocytes embedded in fibrin and a stable resorbable polymer scaffold, for the treatment of clinical symptomatic focal degenerative defects of the knee.

Methods Clinical outcome after 4-year clinical follow-up was assessed in 19 patients with preoperatively radiologically confirmed osteoarthritis and a Kellgren-Lawrence score of 2 or more. Clinical scoring was performed before implantation of the graft and 6, 12, and 48 months after implantation using the Lysholm score, the Knee injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee (IKDC) score, and the International Cartilage Repair Society (ICRS) score. Cartilage regeneration and articular resurfacing were assessed by magnetic resonance imaging (MRI) 4 years after implantation of the autologous cartilage graft.

Results Significant improvement ($P < 0.05$) of the Lysholm and ICRS scores was observed as early as 6 months after implantation of BioSeed®-C and remained stable during follow-up. The IKDC score showed significant improvement compared with the preoperative situation at 12 and 48 months ($P < 0.05$). The KOOS showed significant improvement in the subclasses pain, activities of daily living, and knee-related quality of life 6 months as well as 1 and 4 years after implantation of BioSeed®-C in osteoarthritic defects ($P < 0.05$). MRI analysis showed moderate to complete defect filling with a normal to incidentally hyperintense signal in 16 out of 19 patients treated with BioSeed®-C. Two patients without improvement in the clinical and MRI scores received a total knee endoprosthesis after 4 years.

Conclusions The results show that the good clinical outcome achieved 1 year after implantation of BioSeed®-C remains stable over the course of a period of 4 years and suggest that implanting BioSeed®-C is a promising treatment option for the repair of focal degenerative defects of the knee.

Introduction Cartilage lesions of the knee occur frequently and represent a major health problem. Consecutive knee arthroscopies showed that up to 63% of the patients with knee-related symptoms suffered from chondral or osteochondral defects [1,2]. These defects comprise focal osteochondral or chondral lesions in 67%, osteoarthritic defects in 29%, lesions related to osteochondritis dissecans in 2%, and other defects in 1% of the cases [3]. Recently, a variety of surgical techniques that aim for resurfacing and regenerating of the articular cartilage have evolved. In the clinical routine, debridement, bone marrow-stimulating techniques, osteochondral autograft transfer, and autologous chondrocyte implantation (ACI) are commonly used cartilage repair techniques [4-8].
The first ACI was performed in 1987, and the clinical study of Brittberg and colleagues [4] in 1994 represents the starting point of cell-based cartilage repair and regenerative medicine. Up to now, more than 15,000 patients worldwide have been treated with ACI [9], and various reports documented the clinical effectiveness of implanting autologous culture-expanded chondrocytes for cartilage repair [10-13]. Although there is no significant evidence that ACI produces superior clinical results for the treatment of full-thickness articular cartilage defects compared with other cartilage repair interventions [14,15], it is regarded as a second-line treatment for small defects and a first-line treatment for defects larger than 2 to 4 cm² [16].

For ACI, a small partial or full-thickness cartilage biopsy is taken from a less weight-bearing area of the healthy articular cartilage. The chondrocytes are harvested by enzymatic digestion and cells are grown with autologous serum. For chondrocyte implantation, a periosteal flap or a collagen sheet is sutured to the surrounding healthy cartilage rim, creating a reservoir for the injection of the autologous chondrocyte cell suspension. The need for an intact cartilage rim limits the use of ACI to some regions of the knee, and the covering of the chondrocyte suspension with a periosteal flap or a collagen sheet may be insecure (for instance, in degenerative defects that often miss an intact cartilage rim). In addition, potential sources of complications may include periosteal hypertrophy, loosening of the periosteal flap, atrophy, and loss of cells into the joint cavity [17-19]. These technical disadvantages of ACI result in re-operations in up to 25% to 36% of the patients [20,21]. Therefore, cartilage tissue engineering grafts that address these disadvantages by using three-dimensional scaffolds stabilizing the graft and the regenerative potential of autologous chondrocytes were developed. Meanwhile, clinical results have shown the effectiveness of hyaluronan-based [22,23], collagen-based [24,25], and resorbable polymer-based [26] autologous chondrocyte grafts for the repair of cartilage defects.

Currently, ACI is contraindicated in osteoarthritic patients. Nevertheless, preclinical studies suggest that chondrocytes or mesenchymal stem cells from osteoarthritic patients may have the capacity to form cartilage repair tissue and fulfill the prerequisites for use in ACI [27,28]. However, for cell-based cartilage therapies in osteoarthritis, it is important to harvest unaffected healthy cartilage biopsies since healthy chondrocytes have been shown to form a cartilage tissue in vitro that shows better morphology and a higher proteoglycan content than chondrocytes derived from osteoarthritic joints [29]. Clinically, it has been shown that microfracture treatment of patients with moderate osteoarthritis improved their pain and activity of daily living and significantly widened the joint spaces 1 year after treatment compared with the preoperative situation [30]. The effectiveness of a second-generation cartilage graft based on hyaluronan has been shown for the treatment of osteoarthritic knees with osteoarthritis not inhibiting the regeneration sequence [31].

Recently, it was shown that the autologous cartilage graft BioSeed®-C (BioTissue Technologies GmbH, Freiburg, Germany) based on a bioresorbable two-component gel-polymer scaffold is effective for the treatment of traumatic and focal osteoarthritic cartilage defects of the knee [26]. The aim of the present study was to evaluate ACI using BioSeed®-C for the treatment of mild degenerative and focal osteoarthritic defects of the knee. Magnetic resonance imaging (MRI) analysis of the cartilage repair tissue as well as the clinical evaluation of a series of 19 patients with pre-existing osteoarthritic symptoms and a 4-year clinical follow-up document the effectiveness of BioSeed®-C for the treatment of focal degenerative cartilage defects.

Materials and methods

Patients

From December 2001 to October 2002, 79 patients with traumatic and degenerative chondral defects of the knee joint were treated with a second-generation ACI (BioSeed®-C). Patients suffered from traumatic, mild degenerative, or osteoarthritic and symptomatic defects of the articular cartilage of the knee which were clinically significant [26]. The study was performed in compliance with the ethical review board of the University of Freiburg, Germany. All patients gave their consent to participate. Radiographs were taken preoperatively, and osteoarthritic degenerations were evaluated by two independent observers using the Kellgren-Lawrence scoring system. The observers were blinded to the procedure. A Kellgren-Lawrence score of greater than or equal to 2 defines osteoarthritis [32] and was found in 24 patients. Nineteen patients gave consent to a clinical follow-up of 4 years. Clinical examinations were performed at 0, 6, 12, and 48 to 60 months.

Characteristics of patients with degenerative cartilage defects are presented in Table 1. The average age of patients (8 females and 11 males; mean body mass index of 25, ranging from 19 to 34) was 35 years (25 to 50 years). The mean defect size of the first lesion was 4 cm² (2 to 6 cm²). All defects (first lesion) were classified as Outerbridge class IV [33] and were located on the medial femoral condyle (n = 14), the lateral femoral condyle (n = 2), or the patella (n = 3). Four patients had a second chondral defect that was treated with ACI as well. Previous surgical procedures were shaving (n = 10), abrasion arthroplasty (n = 4), drilling/microfracture (n = 1), meniscectomies (n = 6), anterior cruciate ligament/collateral ligament reconstructions (n = 7), or high tibial osteotomy (n = 5).

Implantation of BioSeed®-C and follow-up treatment

For preparation of BioSeed®-C, autologous chondrocytes were harvested from healthy cartilage (approximately 250 mg) of a less weight-bearing area of the knee. One hundred milliliters of whole blood was collected with a conventional blood-
sampling system (Sarstedt AG, Nümbrecht, Germany) and used for autologous chondrocyte growth. Twenty million chondrocytes were rearranged in fibrin and a polymer-based scaffold (2 × 3 cm and 0.2 cm in height) of polyglycolic/polyactic acid (polyglactin, vicryl) and polydioxanone. After careful debridement of the defective cartilage down to the subchondral bone, the graft was fitted to the size of the defect and implanted arthrotomically. Fixation of the graft (Figure 1) was achieved by transosseous anchoring as described previously [34]. Starting the day after surgery, patients were subjected to continuous passive motion. For 6 weeks, partial loading with 15% of body weight as well as isometric tension exercises were allowed. In weeks 7 to 12, patients increased the loading and performed strengthening exercises and active physiotherapy at a gentle level. From week 13 on, patients gradually increased the weight and performed muscular and coordination exercises up to full weight-bearing. Gentle exertion was allowed after 6 months and more strenuous activities and contact sports after 12 months.

**Evaluation of clinical results**

For evaluation of clinical results after implantation of BioSeed®-C, the Lysholm score [35], the Knee injury and Osteoarthritis Outcome Score (KOOS) [36], and the International Knee Documentation Committee (IKDC) Knee Examination Form [37] were applied. The Knee Examination Form (surgeons’ part) of the International Cartilage Repair Society (ICRS) cartilage injury evaluation package evaluates the subgroups knee joint effusion, passive motion deficit, ligaments, compartment, harvest site pathology, joint space, and functionality [38]. The score was applied and grading was performed from 1 (normal) to 4 (severely abnormal). The lowest grade within a group determines the group rate, and the worst group grade determines the final evaluation. The clinical situation was documented before and 6, 12 as well as 48 to 60 months after implantation of the graft. Forty-eight to sixty months after transplantation, repair and resurfacing of cartilage defects (n = 17) were evaluated with a state-of-the-art 1.5 Tesla MRI scanner (Siemens AG, Erlangen, Germany) and the Henderson scoring system was applied [13]. Hypertrophic changes were classified with the Kreuz score [19].
Statistical analysis
For statistical analysis of the Lysholm and ICRS scores, the Kruskal-Wallis test and the one-way analysis of variance (ANOVA) of ranks test were used. For isolating the groups that differed significantly \( (P < 0.05) \) from the others, the all-pairwise multiple comparison procedure (Dunn's method) was applied. Statistical analysis of the IKDC data was performed using ANOVA followed by the \( t \) test. Differences were considered significant at a \( P \) value of less than 0.05. For analysis of the KOOS, the non-parametric Mann-Whitney rank sum test was applied and differences were considered significant at a \( P \) value of less than 0.05. All comparisons were performed between scorings at every individual point in time of the follow-up period compared with the preoperative scores.

Results
Postoperative findings in patients with focal degenerative cartilage defects treated with BioSeed®-C
BioSeed®-C was implanted arthroto mically using a transosseous fixation technique (Figure 1). The degenerated cartilage was debrided down to the subchondral bone, and the graft was fitted to the size of the defect. For fixation, the graft was armed in each corner with resorbable threads forming loops that were secured by threefold knots (Figure 1a). On every corner of the defect, a k-wire with a thread guide was drilled using the inside-out technique (Figure 1b). The k-wires that carry guiding threads thread through the guide of the k-wire, and the loops of the graft were pulled (inside-out) through the femoral bone (Figure 1c). The threefold knots act as anchors that seize within the subchondral bone and thus securely fix the graft in the defect (Figure 1d).

BioSeed®-C was implanted in focal degenerative cartilage defects of knees that showed radiological signs of osteoarthritic degeneration (Figure 2). Applying the Kellgren-Lawrence score to the preoperatively performed radiographs showed that 24 patients had osteoarthritis with a Kellgren-Lawrence score of 2 with constriction of the joint space (Figure 2a, black arrowhead) or a score of 3 with constriction and formation of osteophytes (Figure 2b, white arrowheads). Nineteen out of twenty-four patients gave consent to clinical follow-up conducted 4 years after implantation of the graft. Postoperatively, no clinical signs of persistent knee joint infection or allergic reactions were evident. Knee joint effusion or swelling was reported by 9 patients. Symptoms of temporary blocking were observed in 4 out of 19 patients. None of the patients acquired potentially graft-related autoimmune disorders or signs of hypersensitivity. There were no signs of malignant transformation, migration of chondrocytes, poisoning, toxicity, organ failure, hepatic or renal disorders, or reproductive defects or teratogenic effects. There were no signs of loosening, de-bonding, or ablation of the graft. Minimal asymptomatic cartilage hypertrophic changes (<125%) were found in 3 patients, and abnormal cartilage growth was not evident. Nine patients were subjected to second-look arthroscopy due to symptoms like persistent grinding, catching, pain, or swelling. The newly formed repair tissue showed good integration and bonding as well as a visible contrast in color to the surround-
ing tissue. In 1 patient, multiple lesions scattered across the defect site and the retropatellar cartilage were observed. In 2 patients, a new cartilage lesion in the surroundings of the transplanted area was detected and treated with abrasion chondroplasty. In two other patients with persistent pain, the ACI procedure failed and a total knee endoprosthesis was implanted 4 years after implantation of the graft.

Clinical evaluation of surgical results four years after implantation of BioSeed®-C

As assessed by the Lysholm score, statistically significant improvements ($P < 0.05$) were observed as early as 6 months after implantation of BioSeed®-C (Figure 3). Compared with preoperative findings, the median Lysholm score significantly improved ($P < 0.05$), increasing from 55.0 to 89.0 in patients with focal osteoarthritic degeneration 4 years after implantation of the graft. The clinical outcome 4 years after implantation of BioSeed®-C in osteoarthritic focal defects was evaluated using the IKDC subjective knee evaluation score and the ICRS score (Figure 4). The IKDC score (Figure 4a) showed significant improvement 1 year ($P = 0.0068$) and 4 years ($P = 0.0017$) postoperatively compared with the preoperative situation. The mean score increased from 49.0 to 70.1 after 4 years. In addition, the ICRS score improved significantly ($P < 0.05$) over the whole study period from 4.0 preoperatively to 2.0 at 4-year follow-up (Figure 4b).

The KOOS describes the patient’s view about his knee and associated problems (Figure 5). At 6-month, 1-year, and 4-year follow-up, the patients’ status improved significantly ($P < 0.05$) compared with preoperative findings. The median scores increased in the subclasses pain (69 to 89), activities of daily living (72 to 96), and knee-related quality of life (25 to
56) 4 years after implantation of the graft. Patients showed a significant improvement in the subclass sports and recreation (10 to 65) 4 years after implantation, whereas the subclass symptoms showed no significant improvement ($P > 0.05$) of the score (71 to 82). Both patients who needed total knee replacement after 4 years did not improve in the scores over the study period ($P < 0.05$). After 48 months, the Lysholm score was 38.5 (24 to 53) points and the KOOS subclasses symptoms and activity of daily life were 41 (38 to 44) points each and significantly worse compared with the results of the other patients ($P < 0.05$).

**Magnetic resonance imaging four years after transplantation of BioSeed®-C**

Two patients had to undergo revision surgery and received a total knee endoprosthesis. Therefore, 17 out of 19 patients were analyzed by MRI 4 years after implantation of BioSeed®-C. Patients with degenerative cartilage defects treated with BioSeed®-C showed moderate to complete filling of the defects (Figure 6). Eleven patients showed a complete filling of the defect with cartilage repair tissue (Figure 6a). In 5 patients, the defects were filled more than 50% (Figure 6b), and 1 patient showed a defect fill of less than 50% (Figure 6c). The transosseous drill holes were still visible (Figure 6a,c, white arrowheads). Representative MRIs as assessed preoperatively and at 4-year follow-up (Figure 7) show that cartilage defects at the medial femoral condyle (Figure 7a,b) and patellar defects (Figure 7c,d) were completely filled with cartilage repair tissue after transplantation of the graft. A detailed MRI analysis according to Henderson and Kreuz is given in Table 2. The cartilage signal in 16 out of 17 defects was normal or showed slight alterations in the intensity. In one defect, the signal was hyperintense throughout large areas of the repair tissue. Strong to moderate subchondral edema was evident in 6 patients, and 11 out of 17 patients showed no or mild edema. Five patients showed moderate to strong signs of knee joint effusion. No to mild knee joint effusion was evident in 12 out of 17 patients treated with BioSeed®-C at 4-year follow-up. Both patients who sustained a total knee endoprosthesis after 4 years had the last control MRI after 12 months. The defect area was partially filled (<50%) with a hyperintensive repair tissue and showed a concomitant moderate subchondral edema.

**Discussion**

The autologous gel-polymer cartilage graft, BioSeed®-C, uses the well-known regenerative capacity of autologous chondrocytes, gel-like matrices for promoting tissue formation, and the initial mechanical stability of resorbable polymer scaffolds for cartilage repair [39]. The assembly of chondrocytes in polymer-based scaffolds ensures the even distribution of a high number of vital chondrocytes within the graft and has been shown to allow the production of cartilage grafts that develop toward hyaline cartilage *in vitro* [40]. In particular, the embedding of culture-expanded chondrocytes in fibrin and polymer-based scaffolds made of polyglycolic acid or copolymers of polyglycolic and polylactic acid initiates chondrocyte redifferentiation *in vitro* and allows for formation of cartilage matrix *in vivo* after implantation of the graft [41,42]. The formation of cartilage repair tissue after implantation of the polymer-based graft made of non- and cryo-preserved chondrocytes has been shown in the rabbit joint defect model [43] as well as in a large animal horse model. In Haflinger horses, full-thickness cartilage defects of the fetlock joint were treated with the autologous polymer-based cartilage graft, and formation of a hyaline-like cartilage repair tissue as well as firm bonding of the graft to the adjacent healthy cartilage and to the subchondral bone tissue were evident 1 year after implantation [44]. Since the chondrocytes are embedded in and protected by the fibrin-
polymer matrix, BioSeed®-C allows for easy handling of the graft during surgery, avoids the use of cover materials like perios-teum or collagen sheets, needs no healthy cartilage rim surrounding the defect, and ensures arthroscopical implantation and secure fixation [34]. In particular, the secure fixation of cartilage grafts is of importance to avoid transplant loosening, debonding of the graft or ablation, and in turn clinical complications and re-operations. As assessed in recent biomechanical studies, stable second-generation cartilage grafts for ACI like BioSeed®-C allow good anchoring of the graft in the defect by fibrin gluing, chondral or transosseous suturing, and resorbable pin fixation [45-47]. From the cellular point of view, particularly in an osteoarthritic environment, joint homeostasis and the composition of the synovial fluid may be of special importance in cartilage repair. In a goat model, it has been shown that defects showed better repair when the lesion was covered immediately with periosteeum compared with defects that were left untreated before transplantation [48]. Using a chick limb bud assay, synovial fluid from patients with acute traumatic cartilage defects has been shown to stimulate chondrogenesis, but synovial fluid from patients with chronic traumatic defects predominantly inhibited chondrogenic development [49]. In contrast, synovial fluid obtained from patients suffering from trauma, osteoarthritis, or inflammatory rheumatoid arthritis stimulated the synthesis of proteoglycans in a bovine model, with osteoarthritis and trauma synovial fluid showing a markedly increased synthesis compared with rheu-matoid arthritis [50]. In a rabbit model, it has been shown that synovial fluid promotes and enhances cartilage tissue development from perichondrium [51]. Although the influence of synovial fluid or components of the fluid on cartilage repair remains unclear and further studies are needed, it is evident that an altered joint environment may influence tissue regeneration. Cartilage repair should be performed as early as possible and an inflammatory environment should be avoided.

From the clinical point of view, the use of autologous chondrocytes in suspension like in first-generation ACI has been shown to be effective for the repair of localized traumatic defects [10,11,52]. Second-generation cartilage grafts using scaffolds based on collagen or hyaluronan for stabilizing autologous chondrocytes are considered to be technically more attractive than first-generation ACI and have been shown to be clinically as effective as ‘classical’ ACI [22,24]. In a recent report of the treatment of traumatic and degenerative defects [26] and in this case series, we demonstrated the safety and effectiveness of the autologous cartilage gel-polymer graft BioSeed®-C for the treatment of challenging defects like large focal degenerative full-thickness cartilage lesions of the knee. After 1-year follow-up, mean scores increased significantly between 30% and 51% compared with the preoperative situation, depending on which score was analyzed. These good results lasted and showed significant improvement of the mean scores between 34% and 55% 4 years after implantation of the graft. This indicates a significant decrease in the patients’ pain and knee instabilities during activity as well as a significant increase in patients’ quality of life. The implantation of BioSeed®-C in focal osteoarthritic defects showed significant improvement in the KOOS subclasses pain, activity of daily living, and quality of life 1 year and 4 years after implantation of the graft. Obviously, the efficacy of the polymer-based autologous cartilage graft BioSeed®-C for the repair of osteoarthritis cartilage defects is shown by the improvement of clinical scores, by patients’ pain and quality of life as well as by the good filling of the defects with repair tissue as assessed by MRI. This is of special relevance since the BioSeed®-C-mediated cartilage repair was achieved in a challenging patient cohort with clinically osteoarthritic symptoms and focal cartilage degeneration 1 and 4 years after implantation of the graft. Interestingly, the status of the patient 2 years after ACI is considered an important indicator for the future outcome. During this time, most of the complications of cell-based cartilage repair as well as improvement in clinical scores and subjective patient satisfaction were found. On the other hand, indicators of a worse outcome like multiple surgical procedures, higher age, and large defects correspond to findings published by
After implantation of BioSeed®-C, 9 out of 19 patients were subjected to second-look arthroscopy due to symptoms like grinding, catching, pain, or swelling. This re-intervention rate, though for diagnostic purposes, is relatively high and may be related to this challenging patient cohort with a considerable number of concomitant surgeries like high tibial osteotomy and anterior cruciate ligament reconstruction. However, only 4 out of the 19 patients (21%) had to undergo revision surgery or re-operation. This is in concordance with other studies reporting rates of revision surgery of between 0% [56] and 25% [20]. Two patients were treated with an abrasion chondroplasty for newly formed cartilage lesions beside the transplanted area. Two additional patients out of the 19 patients received a total knee endoprosthesis and were classified as ‘graft failure’, although there is no evidence that the prosthesis was indicated because of a failure of BioSeed®-C. This failure rate of 10% corresponds to earlier findings describing rates of failure in ACI with other implants of between 5% [12] and 13% [20]. These patients with focal degenerative defects treated with the chondrocyte graft were young and in the mid to long term may have no treatment option other than total knee arthroplasty. Alternate treatment strategies such as ACI may lead to several re-interventions and dissatisfied patients but may postpone total knee arthroplasty as possibly the only option for these patients and are therefore considered a good treatment for focal degenerative cartilage defects. However, long-term studies are needed to evaluate whether cell-based cartilage grafts prevent total joint replacement in osteoarthritis. After 6 months, there was no difference in the scores of these 2 patients with an endoprosthesis and the rest of the study group. After 12 months, these two patients with a ‘graft failure’ had not yet improved and revealed worse results compared with the other patients. After 12 months or after 48 months, neither of the 2 patients reached 55 points in the Lysholm score or 45 points in the IKDC score, indicating that there might be a threshold for long-term graft survival and successful tissue regeneration. Even if graft regeneration takes a long time (from 2 to 3 years after surgery), a continuous improvement should be detected 6 to 12 months after surgery. In this context, the lack of clinical improvement, combined with insufficient MRI results, may be signs of long-term graft failure. In general, re-operations and graft failure after implantation of chondrocytes in a first-generation ACI procedure are caused by problems associated with the periosteal flap [12,18,57]. This inherent technical disadvantage of the original ACI procedure does not occur when using second-generation ACI grafts like BioSeed®-C that are void of any cover materials. In addition, the easy and secure fixation of BioSeed®-C along with the lack of any covering may reduce the operating time and may result in a less invasive procedure since there is no need to harvest periosteum from the tibia. Limitations of the study are the small number of patients and the lack of a control group. Since this observational case report study was initiated first to gain insights in the safety and effectiveness of treating consecutive cartilage defects with BioSeed®-C, the study is...
Table 2

| Characteristic               | Magnetic resonance imaging score |
|------------------------------|----------------------------------|
| Defect filling               | 1 (normal)                       |
| 11 (complete filling), including 3 with minimal hypertrophic changes (<125%) | 2 (mild) 5 (>50%) 1 (<50%) 0 (no filling) |
| Signal intensity             | 8 (normal)                       |
| 8 (some hyperintense areas)  | 1 (hyperintense areas) 0 (no signal) |
| Subchondral edema            | 4 (no edema)                     |
| 7 (mild edema) 5 (moderate edema) 1 (distinct edema) |
| Effusion                     | 1 (no effusion)                  |
| 11 (mild effusion) 4 (moderate effusion) 1 (distinct effusion) |

Further limited by the lack of predefined primary outcome goals. The study was not performed in a randomized controlled manner in comparison with an appropriate control group or with an alternate treatment option like microfracturing. Furthermore, in young patients, degeneration of cartilage can be observed after trauma whereas well-defined osteoarthritis occurs predominantly in older patients. Therefore, first- or second-generation ACI will not be recommended unrestrictedly for the treatment of focal osteoarthritic cartilage defects. However, this is the first study showing long-term results using the second-generation ACI graft BioSeed®-C in patients with osteoarthritic and/or degenerative changes of the knee. The study presents a continuous objective patient evaluation including clinical scores and control MRI over the course of a period of 4 years.

Conclusions
This extensive case report shows promising results after implantation of the second-generation autologous cartilage graft, BioSeed®-C, for the treatment of focal degenerative cartilage defects of the knee. Clinical evaluation 4 years after implantation showed that the treatment of focal osteoarthritic defects with BioSeed®-C leads to significant improvement of the patients’ condition as documented by reliable clinical outcome scores and by cartilage regeneration as well as articular resurfacing as assessed by MRI. The good clinical results found 1 year after implantation of BioSeed®-C lasted and remained stable for at least 4 years. Nevertheless, further long-term studies are needed to evaluate whether cell-based cartilage grafts prevent total joint replacement in osteoarthritis.

Competing interests
CK is an employee of TransTissue Technologies GmbH, which is a subsidiary of BioTissue Technologies GmbH (Freiburg, Germany). BioTissue Technologies GmbH produces and distributes BioSeed®-C. CE works as a consultant for BioTissue Technologies GmbH. All other authors declare that they have no competing interests.

Authors’ contributions
PCK helped to carry out the data evaluation, to draft the manuscript, and to perform the patient data collection and participated in data evaluation. CK helped to carry out the data evaluation and to draft the manuscript. SM and CO helped to perform the patient data collection and participated in data evaluation. CE conceived the study, participated in its design and coordination, performed the surgical procedures, and was involved in the patient data collection and interpretation. All authors read and approved the final manuscript.

Acknowledgements
None of the authors received funding for this study, for the study design, for the collection, analysis and interpretation of data, or for preparing the manuscript. No funding body had a role in the decision to submit the manuscript for publication. Information or clinical photographs relating to individual patients were made anonymous. Consent for the study was obtained from each patient.

References
1. Curl WW, Krome J, Gordon ES, Rushing J, Smith BP, Poehling GG: Cartilage injuries: a review of 31,516 knee arthroscopies. *Arthroscopy* 1997, 13:456-460.
2. Hjelle K, Solheim E, Strand T, Muri R, Britberg M: Articular cartilage defects in 1,000 knee arthroscopies. *Arthroscopy* 2002, 18:730-734.
3. Widuchowski W, Widuchowski J, Trzaska T: Articular cartilage defects: study of 25,124 knee arthroscopies. *Knee* 2007, 14:177-192.
4. Britberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Petersson L: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N Engl J Med* 1994, 331:889-895.
5. Hubbard MJ: Articular debridement versus washout for degeneration of the medial femoral condyle. A five-year study. *J Bone Joint Surg Br* 1996, 78:217-219.
6. Matsusue Y, Yamamuro T, Hama H: Arthroscopic multiple osteochondral transplantation to the chondral defect in the knee associated with anterior cruciate ligament disruption. *Arthroscopy* 1993, 9:318-321.
7. Steadman JR, Rodkey WG, Rodrigo JJ: Microfracture: surgical technique and rehabilitation to treat chondral defects. *Clin Orthop Relat Res* 2001, 391:S362-369.
8. Kreuz PC, Steinwachs MR, Erggelet C, Krause SJ, Konrad G, Uhl M, Sudkamp N: Results after microfracture of full-thickness chondral defects in different compartments in the knee. *Osteoarthritis Cartilage* 2006, 14:1119-1125.
9. Minas T: Autologous chondrocyte implantation in the arthritic knee. *Orthopedics* 2003, 26:943-947.
10. Browne JE, Anderson AF, Anciero R, Mandelbaum B, Moseley JB Jr, Micheli LJ, Fu F, Erggelet C: Clinical outcome of autologous cartilage grafts prevent total joint replacement in osteoarthritis.
chondrocyte implantation at 5 years in US subjects. Clin Orthop Relat Res 2005, 436:237-245.
11. Knutzen G, Dengaet JO, Engerbretsen L, Grontvedt T, Isaksen V, Ludvigsen TC, Roberts S, Solheim E, Strand T, Johansen O: A randomized trial comparing autologous chondrocyte implantation with microfracture. Findings at five years. J Bone Joint Surg Am 2007, 89:2105-2112.
12. Peterson L, Minas T, Britberg M, Nilsson A, Sjogren-Jansson E, Lindahl A: Two- to 9-year outcome after autologous chondrocyte transplantation of the knee. Clin Orthop Relat Res 2000, 374:212-234.
13. Hestbaek L, Francisco R, Oakes B, Cameron J: Autologous chondrocyte implantation for treatment of focal chondral defects of the knee – a clinical, arthroscopic, MRI and histo logic evaluation at 2 years. Knee 2005, 12:209-216.
14. Magnusen RA, Dunn WR, Carey JL, Spindler KP: Treatment of randomised study. J Bone Joint Surg Br 2005, 87:640-645.
15. Wasiak J, Clar C, Villaneuva E: Autologous cartilage implantation for full thickness articular cartilage defects of the knee. Cochrane Database Syst Rev 2006, 3:CD003323.
16. Bergström C: Treatment of chondrocyte implantation – technique and long-term follow-up. Injury 2008, 39:S40-49.
17. Diesang IM, Hunziker EB: Delamination rates of tissue flaps used in articular cartilage repair. J Orthop Res 2000, 18:909-911.
18. Micheli LJ, Brownie JW, Erggeleth C, Fu F, Maniscalbba B, Moseley JB, Zurakowski D: Autologous chondrocyte implantation of the knee: multicenter experience and minimum 3-year follow-up. Clin J Sport Med 2001, 11:223-228.
19. Kreuz PC, Steinwachs M, Erggeleth C, Krause SJ, Ossendorf C, Maiher D, Ghaman N, Uhl M, Haag T: Classification of graft hypertrophy after autologous chondrocyte implantation of fullthickness cartilage defects in the knee. Osteoarthritis Cartilage 2007, 15:1339-1347.
20. Minas T: Autologous chondrocyte implantation for focal chondral defects of the knee. Clin Orthop Relat Res 2001, 391:S349-361.
21. Gooding CR, Bartlett W, Bentley G, Skinner JA, Carrington R, Flanagan A: A prospective, randomised study comparing two techniques of autologous chondrocyte implantation for osteochondral defects in the knee: Peerreview covered versus type I/II collagen covered. Knee 2006, 13:203-210.
22. Maracci M, Berruto M, Brocchetta D, Delcogliano A, Ginelli D, Gobbi A, Kon E, Pedemini L, Rosa D, Sacchetti GL, Stefani G, Zanasi S: Articular cartilage engineering with Hyalograft C: 3-year clinical results. Clin Orthop Relat Res 2005, 435:98-105.
23. Nehrer S, Domayer S, Dorotka R, Schatz K, Bindreiter U, Kotz R: Three-year clinical outcome after chondrocyte transplantation using a hyaluronic matrix for cartilage repair. Eur J Radiol 2006, 57:38-42.
24. Bartlett W, Skinner JA, Gooding CR, Carrington RW, Flanagan AM, Briggs TW, Bentle G: Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee: a prospective, nonrandomised study. J Bone Joint Surg Br 2005, 87:640-645.
25. Behrens P, Bitter T, Kurz B, Russlies M: Matrix-associated autologous chondrocyte transplantation/implantation (MACIT/MACI) – 5-year follow-up. Knee 2006, 13:194-202.
26. Ossendorf C, Kaps C, Kreuz PC, Burmester GR, Sittling M, Engerbretsen L: Treatment of focal osteochondral cartilage defects of the knee with autologous polymer-based three-dimensional cartilage grafts: two year clinical results. Arthritis Res Ther 2007, 9:R41.
27. ScharfZH, Schewe B, Benz K, Gaismaier C, Buhring HJ, Stoop R: Chondrogenic potential of human adult menephi cal stem cells is independent of age or osteoarthritis etiology. Stem Cells 2007, 25:3244-3251.
28. Stoop R, Albrecht D, Gaismaier C, Fritz J, Felka T, Rudert M, Acher WK: Comparison of marker gene expression in chondrocytes from patients receiving autologous chondrocyte transplantation versus osteoarthritis patients. Arthritis Res Ther 2007, 9:R60.
29. Yang KG, Sarris DB, Geuze RE, van Rijen MH, Helm YJ van der, Verbout AJ, Greemers LB, Dhert WJ: Altered in vitro chondro genic properties of chondrocytes harvested from unaffected cartilage in osteoarthritic joints. Osteoarthritis Cartilage 2006, 14:561-570.
30. Bae DK, Yoon HK, Song SJ: Cartilage healing after microfracture in osteoarthritic knees. Arthroscopy 2006, 22:367-374.
31. Holandder AP, Dickinson SC, Sims TJ, Brun P, Cortivo R, Kon E, Maracci M, Zanasi S, Borrione A, De Luca C, Pavesio A, Soranzo C, Abatarigel G: Maturation of tissue engineered cartilage implanted in injured and osteoarthritic human knees. Tissue Eng 2006, 12:1787-1798.
32. Kellgren JH, Lawrence JS: Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957, 16:494-502.
33. Outerbridge RE: The etiology of chondromalacia patellae. J Bone Joint Surg Br 1961, 43-B:752-757.
34. Erggelet C, Sitttinger M, Lahm A: The arthroscopic implantation of autologous chondrocytes for the treatment of full-thickness cartilage defects of the knee joint. Arthroscopy 2003, 19:108-110.
35. Lysholm J, Gillquist J: Evaluation of knee ligament surgery results with special emphasis on use of a scoring scale. Am J Sports Med 1982, 10:150-154.
36. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD: Knee injury and Osteoarthritis Outcome Score (KOOS) – development of a self-administered outcome measure. J Orthop Sports Phys Ther 1998, 28:88-96.
37. Irgang JJ, Anderson AF, Boland AL, Harner CD, Kurosaka M, Neyret P, Richmond JC, Sheline KD: Development and validation of the international knee documentation of cartilage subjective knee form. Am J Sports Med 2001, 29:600-613.
38. International Cartilage Repair Society [http://www.cartilage.org]
39. Sitttinger M, Buija J, Minuth WW, Hammer C, Burmester GR: Engineering of cartilage tissue using bioresorbable polymer carriers in perfusion culture. Biomaterials 1994, 15:451-456.
40. Buija J, Sitttinger M, Minuth WW, Hammer C, Burmester G, Kastenbauer E: Engineering of cartilage tissue using bioresorbable polymer fibres and perfusion culture. Acta Otolaryngol 1995, 115:307-310.
41. Endres M, Neumann K, Schroder SE, Vetterlein S, Morawietz L, Ringe J, Sitttinger M, Kaps C: Human polymer-based cartilage grafts for the regeneration of articular cartilage defects. Tissue Cell 2007, 39:293-301.
42. Kaps C, Frauenenschuh S, Endres M, Ringe J, Haisch A, Lauber J, Buer J, Krenn V, Haupl T, Burmester GR, Sitttinger M: Gene expression profiling of human articular cartilage grafts generated by tissue engineering. Biomaterials 2006, 27:3617-3630.
43. Forman C, Sitttinger M, Schultz O, Spitzer RS, Schlenzka D, Burmester GR: Tissue engineered cartilage repair using cryopreserved and noncryopreserved chondrocytes. Clin Orthop Relat Res 2002, 378:245-254.
44. Barnemitz D, Endres M, Kruger I, Becker A, Zimmermann J, Wilke I, Bange J, Sitttinger M, Kaps C: Treatment of cartilage defects in horses with polymer-based cartilage tissue engineering grafts. Biomaterials 2006, 27:2882-2889.
45. Zelle S, Zantrop T, Schanz S, Petersen W: Arthroscopic techniques for the fixation of a three-dimensional scaffold for autologous chondrocyte transplantation: structural properties in an in vitro model. Arthroscopy 2007, 23:1073-1078.
46. Knecht S, Erggelet C, Endres M, Sitttinger M, Kaps C, Stuessi E: Mechanical testing of fixation techniques for scaffold-based tissue-engineered grafts. J Biomed Mater Res B Appl Biomater 2007, 83:55-67.
47. Drobnic M, Radosavljevic D, Ravnik D, Pavlovcic V, Hribernik M: Comparison of four techniques for the fixation of a collagen scaffold in the human cadaveric knee. Osteoarthritis Cartilage 2006, 14:337-344.
48. Sarris DB, Dhert WJ, Verbout AJ: Joint homeostasis. The discrepancy between old and fresh defects in cartilage repair. J Bone Joint Surg Br 2003, 85:1067-1076.
49. Rodrigo JJ, Steadman JR, Syfetestad G, Benton H, Silliman J: Effects of human knee synovial fluid on chondrogenesis in vitro. Am J Knee Surg 1995, 8:124-129.
50. Neidel J, Schulze M: Value of synovial analysis for prognosis of matrix synthesis of transplanted chondrocytes. Orthopade 2000, 29:158-163.
51. Skog V, Widmark B, Ohlsen L, Wastesson A: The effect of growth factors and synovial fluid on chondrogenesis in peri-
chondrium. *Scand J Plast Reconstr Surg Hand Surg* 1990, 24:89-95.

52. Fu FH, Zurakowski D, Browne JE, Mandelbaum B, Erggelet C, Moseley JB Jr, Anderson AF, Micheli LJ: *Autologous chondrocyte implantation versus debridement for treatment of full-thickness chondral defects of the knee: an observational cohort study with 3-year follow-up.* *Am J Sports Med* 2005, 33:1658-1666.

53. Peterson L, Brittberg M, Kiviranta I, Akerlund EL, Lindahl A: *Autologous chondrocyte transplantation. Biomechanics and long-term durability.* *Am J Sports Med* 2002, 30:2-12.

54. Welsch GH, Mamisch TC, Hughes T, Zilkens C, Quirbach S, Scheffler K, Kraff O, Schweitzer ME, Szomolanyi P, Trattnig S: *In vivo biochemical 7.0 Tesla magnetic resonance: preliminary results of dGEMRIC, zonal T2, and T2* mapping of articular cartilage.* *Invest Radiol* 2008, 43:619-626.

55. Sans DB, Vanlauwe J, Victor J, Haspl M, Bohnsack M, Fortems Y, Vandekerckhove B, Almqvist KF, Claes T, Handelberg F, Lagae K, Bauwhede J van der, Vandenneucker H, Yang KG, Jelic M, Verdonk R, Veulemans N, Bellemans J, Luyten FP: *Characterized chondrocyte implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial versus microfracture.* *Am J Sports Med* 2008, 36:235-246.

56. Loehnert J, Ruhnau K, Gossen A, Bertramann K, Wiese M: *Autologous chondrocyte transplantation (ACT) in knee joints. First clinical results.* *Arthroskopie* 1999, 12:34-42.

57. Minas T, Peterson L: *Advanced techniques in autologous chondrocyte transplantation.* *Clin Sports Med* 1999, 18:13-44.